Endocrine Abstracts

Introduction: Ectopic Cushing’s syndrome (ECS) is a rare endocrine condition caused by corticotrophin (ACTH) hypersecretion of nonpituitary neoplasms. Thymic neuroendocrine tumours (NETs) account for about 5-10% of ECS cases, typically with aggressive clinical course.Case Report: A 31-year-old previously healthy female presented to the emergency department with a 3-week history of fatigue, muscle weakness, headaches and generalized swelling. Physica...

Introduction: Pituitary apoplexy (PA) is a rare but potentially life-threatening complication that may occur in pituitary neuroendocrine tumors (PitNETs). Non-functioning PitNETs (NF-PitNETs), specifically macroadenomas, seem to have a higher risk of apoplexy. Case description: A 45-year-old male presented to the emergency unit with a one-week history of binocular visual deterioration (blurred vision, diplopia, visual field defect) with left-side predomi...

Introduction: Pancreatic neuroendocrine neoplasms (Pan-NENs) account for 1-2% of all pancreatic tumors. Adrenocorticotropic hormone (ACTH)-producing PanNEN is an extremely rare neuroendocrine tumor that accounts for approximately 4-16% of ectopic ACTH-dependent Cushing’s syndrome.Clinical case : A 58-year-old female with arterial hypertension and type 2 diabetes was referred to the Endocrinology Department due to abdominal pain, muscle weakness, and...

Background: Osilodrostat (potent oral 11β-hydroxylase inhibitor) provided rapid normalisation of mean urinary free cortisol (mUFC) in Cushing’s disease (CD) patients during the 48-week (W) core period of LINC 4 (NCT02697734) and was well tolerated. We report long-term efficacy and safety results from the LINC 4 core and extension phases.Methods: 73 adults with CD and mUFC >1.3 upper limit of normal (ULN) were enrolled. LINC 4 comprised a 12...

Background: Cushing’s disease (CD) is associated with hypercortisolism-induced cardiovascular morbidity and mortality and impaired patient quality of life (QoL). We report long-term effects of osilodrostat (potent 11β-hydroxylase inhibitor) on cardiovascular/metabolic-related risk factors, physical features of hypercortisolism and QoL in CD patients following the core and extension phases of the LINC 4 study (NCT02697734).Methods: LINC 4 compri...

Introduction: In two Phase III studies (LINC3, NCT02180217; LINC4, NCT02697734), osilodrostat, (potent oral 11β-hydroxylase inhibitor), provided rapid, sustained reductions in mean urinary free cortisol (mUFC) and late-night salivary cortisol (LNSC), alongside improvements in clinical signs of hypercortisolism and health-related quality of life (HRQoL), in Cushing’s disease (CD) patients. mUFC and LNSC are recommended for monitoring treatment response. We assessed wh...

Diagnosis and treatment of Cushing’s disease is one of the greatest challenges of modern endocrinology. This is related to the fact that pituitary corticotropinomas are small tumours that are difficult to visualize in magnetic resonance imaging (MR). In about 40% of patients with Cushing’s disease, MR scans of the pituitary gland do not reveal any changes. The method that allows to localize the source of adrenocorticotropin (ACTH) secretion is bilateral inferior pe...

IntroductionOsilodrostat, a potent, oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during a Phase III, randomized-withdrawal study. We now report findings from a Phase III study of osilodrostat in patients with CD that featured an initial double-blind, randomized, placebo-controlled period (LINC 4; NCT02697734).MethodsAdults with CD (mUFC > 1.3 &...